Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Hospital Readmission Patterns Post-MI in China Differ Markedly From in the US

Yael L. Maxwell

December 07, 2017

News Daily News

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

L.A. McKeown

December 01, 2017

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Shelley Wood

November 14, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

Todd Neale

August 29, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

Caitlin E. Cox

April 25, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

Advertisement

Hospital Readmission Patterns Post-MI in China Differ Markedly From in the US

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Blood in Urine Carries Consequences for Patients on Antithrombotics

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

P2Y12 Inhibitor Pretreatment Questioned in STEMI

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content